Pharmacology

Anticoagulation Options in Prevention of Atrial Fibrillation-Related Stroke
Stroke may be the first presenting symptom of atrial fibrillation and the consequences are dire. The goal of this activity is to raise awareness of the need to identify patients at risk for atrial fibrillation and ensure effective stroke prophylaxis.
Website


Anticoagulation Questions and Controversies
To explain the multitude of risk factors for AF related thromboembolism including commonly used and newer scoring algorithms To explain the appropriate use of novel anticoagulants and vitamin K antagonists in specific patient populations, focusing particularly on the question of what constitutes valvular heart disease To identify methods to reverse anticoagulation in emergency situations and for surgery.
Website


Are Patients with Atrial Fibrillation Being Optimally Treated?
Distinguish recommendations for anticoagulant use in atrial fibrillation based on the CHA2Ds2-VASc score Evaluate the application of risk calculators for stroke and bleeding among patients with atrial fibrillation, as well as prescriptions for anticoagulants among these individuals.
Website


Assessing the Principles of Practice: Stroke Prevention in the New Era of Anticoagulation
Stroke Prevention in the New Era of Anticoagulation from Medscape Education/Cardiology
Website


Cardiac Risks With Antibiotics Azithromycin, Levofloxacin Supported by VA Data
Data from a large cohort of patients enrolled at US Veterans Affairs (VA) medical centers support recent conclusions that treatment with the antibiotic azithromycin (Zithromax/Zmax, Pfizer) significantly increases the risk of death and cardiac arrhythmia in the first five days of treatment.
Website


Drug and Device Innovations in the World of AF
The goal of this activity is to discuss cardiac monitoring to detect silent AF and anticoagulant strategies to manage these patients at risk for stroke.
Website


FDA Safety Changes: Azithromycin Linked With Fatal Irregular Heart Rhythms CME/CE
This article is intended for primary care clinicians, cardiologists, infectious disease specialists, pharmacists and other specialists who care for patients treated with azithromycin who may be at risk for potentially fatal heart arrhythmias.
Website


Is All VTE the Same?
The goal of this activity is to review the trial data for non-vitamin K antagonist oral anticoagulants (NOACs) in the management of venous thromboembolism (VTE) and the spectrum of VTE disorders.
Website


New Antiarrhythmic Drugs for Atrial Fibrillation
Discussion of new antiarrhythmic drugs including: dronedarone and other "amiodarone analogues," vernakalant, ranolazine and their effectiveness. Powerpoint with audio. HRS.
Website


New Oral Anticoagulant Joins US Atrial-Fib Guidelines
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Website


Pharmacologic Treatment of AF: The Difficult-to-Treat Patient
The goal of this activity is to simulate variables that physicians encounter when managing patients with AF in an office setting.
Website


Secondary Prevention in Acute Coronary Syndrome
Despite optimal therapy with current anticoagulant therapy, patients with ACS carry additional residual risk of cardiovascular death and other ischemic complications. Even in the setting of dual antiplatelet therapy, the risk of death and recurrent ischemic events following ACS reaches approximately 10% within the first year. The goal of this activity is to review the need for more effective antithrombotic therapy.
Website


Secondary Prevention of Atrial Fibrillation-Related Stroke
Stroke may be the first presenting symptom of atrial fibrillation and the consequences are dire. The goal of this activity is to raise awareness of the need to identify patients at risk for atrial fibrillation and ensure effective stroke prophylaxis.
Website


Stroke Prevention Through Improved Anticoagulation Therapy for Patients With Atrial Fibrillation or Flutter
The goal of this activity is to improve clinicians' understanding of the optimal use of anticoagulant therapy in patients with atrial fibrillation.
Website


The Implication of Digoxin Toxicity: A Hospitalist's Perspective CME
Symptoms of digoxin toxicity can be subtle and sometimes missed. The goal of this activity is to provide an overview of digoxin toxicity and strategies for prevention and treatment. Good for credit through 11/01/2014
Website


The Use of New Anticoagulants in Electrophysiology During the Periprocedure Period
ABSTRACT. The introduction of new anticoagulants has ushered in a new and exciting era in the field of hemostasis and thrombosis. These drugs are the first major advance in this area since the vitamin K antagonist (VKA) warfarin was approved over 50 years ago for use as an anticoagulant. The drawback of warfarin has long been recognized, namely unpredictable and variable pharmacology and thus the need for regular anticoagulation monitoring and dose adjustment. The new anticoagulants act via direct thrombin inhibition (dabigatran) or factor Xa (FXa) inhibition (e.g. rivaroxaban, apixaban and endoxaban. Article. Innovations in Cardiac Rhythm Management.
Website


Use of NSAIDs Linked With Risk of Atrial Fibrillation or Flutter
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Website